Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial
Authors:
- Isabela Cristina CoutinhoICIsabela Cristina Coutinho
- Jailson Barros CorreiaJCJailson Barros Correia
- Melania Maria Ramos AmorimMAMelania Maria Ramos Amorim
Open Access
Abstract
Objectives To determine the effectiveness of corticosteroids in reducing respiratory disorders in infants born at 34-36 weeks’ gestation. Design Randomised triple blind clinical trial. Setting A large tertiary teaching hospital in northeast of Brazil. Participants Women at 34-36 weeks of pregnancy at risk of imminent premature delivery. Interventions Betamethasone 12 mg or placebo intramuscularly for two consecutive days. Main outcomes measures Primary outcome was the incidence of respiratory disorders (respiratory distress syndrome and transient tachypnoea of the newborn). Secondary outcomes included the need for ventilatory support, neonatal morbidity, and duration of stay in hospital. Results 320 women were randomised, 163 of whom were assigned to the treatment group and 157 to the controls. Final analysis included 143 and 130 infants, respectively. The rate of respiratory distress syndrome was low (two (1.4%) in the corticosteroid group; one (0.8%) in the placebo group; P=0.54), while the rate of transient tachypnoea was high in both groups (34 (24%) v 29 (22%); P=0.77). There was no reduction in the risk of respiratory morbidity with corticosteroid use even after adjustment for subgroups of gestational age (34-34+6 weeks, 35-35+6 weeks, and ≥36 weeks). The adjusted risk of respiratory morbidity was 1.12 (95% confidence interval 0.74 to 1.70). The need for ventilatory support was around 20% in both groups. There was no difference in neonatal morbidity (88 (62%) v 93 (72%); P=0.08) or in the duration of stay in hospital between the two groups (5.12 v 5.22 days; P=0.87). Phototherapy for jaundice was required less often in babies whose mothers received corticosteroids (risk ratio 0.63, 0.44 to 0.91). Conclusions Antenatal treatment with corticosteroids at 34-36 weeks of pregnancy does not reduce the incidence of respiratory disorders in newborn infants. Trial registration Clinical Trials NCT00675246.Keywords
This publication has 27 references indexed in Scilit:
- Changes in the Gestational Age Distribution among U.S. Singleton Births: Impact on Rates of Late Preterm Birth, 1992 to 2002Seminars in Perinatology, 2006
- Physiology of Fetal Lung Fluid Clearance and the Effect of LaborSeminars in Perinatology, 2006
- Short-Term Outcomes of Infants Born at 35 and 36 Weeks Gestation: We Need to Ask More QuestionsSeminars in Perinatology, 2006
- Antenatal betamethasone and incidence of neonatal respiratory distress after elective caesarean section: pragmatic randomised trialBMJ, 2005
- Cesarean Section, Gestational Age, and Transient Tachypnea of the Newborn: Timing Is the KeyAmerican Journal of Perinatology, 2005
- Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsiaAmerican Journal of Obstetrics and Gynecology, 1999
- The First Chest Radiograph in Neonates Exhibiting Respiratory Distress at BirthClinical Pediatrics, 1997
- Meta-analysis of randomized controlled trials of antenatal corticosteroid for the prevention of respiratory distress syndrome: DiscussionAmerican Journal of Obstetrics and Gynecology, 1995
- Scientific basis and therapeutic regimens for use of antenatal glucocorticoidsAmerican Journal of Obstetrics and Gynecology, 1995
- Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trialBJOG: An International Journal of Obstetrics & Gynaecology, 1989